Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment; Guidance for Industry; Correction

---
identifier: "/us/fr/2024-05081"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment; Guidance for Industry; Correction"
title_number: 0
title_name: "Federal Register"
section_number: "2024-05081"
section_name: "Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment; Guidance for Industry; Correction"
positive_law: false
currency: "2024-03-11"
last_updated: "2024-03-11"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "2024-05081"
document_type: "notice"
publication_date: "2024-03-11"
agencies:
  - "Health and Human Services Department"
  - "Food and Drug Administration"
fr_citation: "89 FR 17475"
fr_volume: 89
docket_ids:
  - "Docket No. FDA-2020-D-1824"
fr_action: "Correction."
---


#  Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment; Guidance for Industry; Correction

**AGENCY:**

Food and Drug Administration, HHS.

**ACTION:**

Correction.

**SUMMARY:**

The Food and Drug Administration (FDA) is correcting a notice that appeared in the *Federal Register* on February 22, 2024. The document announced the availability of a final guidance for industry entitled “Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment.” The document was published with an incorrect docket number. This document corrects that error.

**FOR FURTHER INFORMATION CONTACT:**

David Reasner, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 22, Rm. 6373, Silver Spring, MD 20993, 301-837-7667; or James Myers, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993-0002, 240-402-7911.

**SUPPLEMENTARY INFORMATION:**

In the *Federal Register* of February 22, 2024 (89 FR 13351), in FR Doc. 2024-03622, the following correction is made:

On page 13351, in the first column in the header of the document and in the third column in the second line of the first paragraph, “Docket No. FDA-2024-D-0584” is corrected to read “Docket No. FDA-2020-D-1824.”

Dated: March 5, 2024.

Lauren K. Roth,

Associate Commissioner for Policy.